Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06128551 · ClinicalTrials.gov registry record · Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.

Recruiting
Registry status
Phase 1
Development phase
534
Enrollment target
20
Study locations

NCT06128551 is a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 534 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06128551, a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Revolution Medicines.

RECRUITING
Registry status
Phase 1
Development phase
534 participants
Enrollment target
20
Study locations

Study Summary

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Conditions Studied

Colorectal Cancer Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG Elironrasib
  • DRUG Daraxonrasib

Study Locations (20)

Texas

  • Mary Crowley Cancer Research - Dallas
  • MD Anderson - Houston
  • NEXT Dallas - Irving
  • NEXT Oncology San Antonio - San Antonio
  • START Texas - San Antonio

California

  • City of Hope - Duarte
  • UC IRVINE Health - Orange
  • UC Davis Comprehensive Cancer Center - Sacramento
  • Stanford Cancer Institute - Stanford

New York

  • Columbia University - New York
  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Florida

  • Florida Cancer Specialists - Sarasota
  • Moffitt Cancer Center and Research Institute - Tampa

Michigan

  • Henry Ford Cancer - Detroit
  • START Midwest - Grand Rapids

Colorado

  • University of Colorado Cancer Center - Aurora

Massachusetts

  • Dana Farber Cancer Institute - Boston

Oklahoma

  • University of Oklahoma - Oklahoma City

Trial Details

FieldValue
Enrollment Target 534 participants
Start Date 2023-11-14
Est. Completion 2029-06
Phase Phase 1

Sponsor

Revolution Medicines

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06128551

The ClinicalTrials.gov registry entry for NCT06128551 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (65% lower). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Elironrasib is the first listed.

NCT06128551 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, New York.

Frequently Asked Questions

What is clinical trial NCT06128551 about?

NCT06128551 is a clinical study titled "Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors". This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

What is the current status of trial NCT06128551?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 534 participants. The study started on 2023-11-14. Estimated completion is 2029-06.

What conditions does trial NCT06128551 study?

This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT06128551?

The interventions under investigation include: Elironrasib (DRUG), Daraxonrasib (DRUG).

Who is sponsoring clinical trial NCT06128551?

This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06128551 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.